Edit

Contact Us


    Human Verification

    Liquid Trace™
    is now available
    A Giant Leap in Liquid Biopsy
    Explore Liquid Trace™
    New Expanded Hematology Profiles
    to Cover VEXAS Syndrome and a New Prognostic Biomarker in Myeloproliferative Neoplasms
    Learn More
    Record Breaking TAT
    Receive Your NGS Results in 7 Days or Less
    Learn How to Reduce Your TTI

    Committed to driving the field of oncology diagnostics forward

    Genomic Testing: Answers in
    7 days or less

    Results in 7 days for DNA, 10 days for RNA tests

    Evolving oncology diagnosis, prognosis and precision medicine

    hp-core-technology-sequencing-web-graphic

    Don’t accept
    partial results.

    Advancing Precision in Cancer Diagnostics

    Cancer is a complex disease requiring comprehensive answers. Only a comprehensive answer will allow medical professionals to make the highest quality care decisions for their patients.  At Genomic Testing Cooperative we analyze both DNA and RNA which gives the best possible answers based on our current knowledge. Our tests detect all biomarkers.

    GTC Provides Comprehensive Answers

    Genomic Tests 
    Menu Overview

    Next-generation sequencing of DNA, RNA and cell-free (cfDNA cfRNA) Profiling

    Hematology

    Comprehensive Hematologic Molecular Profiling enables the detection and differentiation of driver and sub-clonal mutations, determines prognosis and identifies targeted therapies for personalized medicine.

    Solid Tumor

    GTC offers comprehensive NGS testing for solid tumors. Our assays cover all clinically relevant genes including tumor mutation burden (TMB), MSI, HRD, fusion/translocations, copy number variation, amplification, and deletions.

    Liquid Biopsy

    Comprehensive Liquid Biopsy genomic testing performed on cell-free DNA (cfDNA) and cell-free RNA (cfRNA) to identify molecular abnormalities in 275 genes. The tests reduce the need for bone marrow biopsy.

    Our genomic testing is focused on comprehensive profiling of DNA and RNA in hematologic neoplasms and solid tumors, embracing the latest sequencing technology and informatics tools, thereby providing better insights into the patient’s tumor signature.

    • GTC’s RNA sequencing capabilities go beyond just the detection of fusions and include alternative splicing, gene expression and prediction.
    • Our RNA profiling can be used to complement flow cytometry and immunohistochemistry (IHC) testing. GTC’s capabilities include liquid biopsy testing that give physicians testing options when tissue or bone marrow isn’t available.
    • GTC’s informatics tools use artificial intelligence with sophisticated algorithms to interpret complex data sets; these informatics tools are unmatched anywhere on the market today.

    Both solid tumors (lung, colon, breast, etc) and hematologic malignancies (leukemia, multiple myeloma, etc) have molecular profiling tests available.

    All major types of cancer have molecular testing that can be performed on them but the sample requirements will be different.

    Solid Tumor
    Detected Genes

    0
    Detected Genes
    0
    RNA Genes
    0
    Liquid Biopsy DNA Genes

    Hematologic Malignancies
    Detected Genes

    0
    DNA Genes
    0
    RNA Genes

    Time Matters On Health Tests

    Heme Panels - DNA
    5.55 Days Average
    Solid Tumor Panels - DNA
    5.8 Days Average
    Heme Plus Panels - DNA & RNA
    8,39 Days Average
    Solid Tumor Plus Panels - DNA & RNA
    8,39 Days Average
    Total Case TAT (Q1, Q2 2022 average)
    6,64 Days Average

    GTC consistently delivers results
    in 10 days or less

    • Comprehensive Hematologic Molecular Profiling enables the detection and differentiation of driver and sub-clonal mutations, determines prognosis and identifies targeted therapies for personalized medicine.
    • Genomic Testing Cooperative also offers comprehensive next generation sequencing of DNA and RNA for solid tumors including cancers of the lung, pancreas, brain, colon, breast, ovary, endometrium, thyroid, head and neck and soft tissue (sarcoma and GIST).
    • Our assays cover all clinically relevant genes including tumor mutation burden (TMB), MSI, HRD, fusion/translocations, copy number variation, amplification, and deletions.
    • Our reports provide full interpretation and presentation of clinical relevance for diagnosis, therapy, prognosis, heterogeneity and potential clinical trials.

    Less than 0.5% of our tests
    result in a QNS (2021-2022 results)

    Extremely Low QNS Rate (Less than 0.5%)
    0.38%
    Extremely Low TNP Rate (Less than 0.5%)
    0.38%

    Reduce your TTI

    Test to Treatment Initialization
    We are committed to serve patients and Doctors quickly

    Record Breaking TAT*

    Results in 5 to 7 days
    We promised to provide reports in 7 days or less. Actually, we do better than that!
    (*maximum 10 days for RNA results)
    Learn More

    Revolutionary Cooperation

    A new way to internalize or outsource
    your genomic profiling for cancer

    Two ways to work together

    You can cooperate Genomic Testing Cooperative by:
    - Outsource Testing
    - Internalize Testing
    Learn More

    COMPREHENSIVE GENOMIC TESTING:

    HEMATOLOGY PANELS

    SOLID TUMOR PANELS

    LIQUID BIOPSY

    Machine/Deep Learning Meets Next Generation Sequencing

    Genomic Testing Cooperative is creating a new kind of disruptive business model. We utilize advanced next-generation sequencing techniques and AI to offer the most innovative testing to our customers. Our co-op model allows customers to select a level of service that suits their oncology testing requirements including:

    1. An in-house genomics lab managed by GTC
    2. Cooperative Associate
    3. Reference lab 

    Genomic testing is expensive and risky for smaller labs because of its complexity and rapidly changing information. Competing with larger labs is challenging to get scale for profitable operations and will face different billing challenges than routine tests.

    GTC alleviates those risks and challenges for our customers handling innovation, medical oversight, operations, and billing. All GTC tests are medicare approved

    GTC has created a co-op model to reduce sales, operations, and service costs – the biggest impediment to profitability. We share our resources with you to cut down overhead. We have a level of membership that works for the smallest labs up to the biggest reference labs.

    To learn more reach out for a capabilities presentation.

    Most labs work on a basis where a client sends a sample and the lab bills either the client or the patient. The relationship is purely transactional.

     

    GTC allows members to join, share resources, share knowledge, have a voice in GTC and collaborate in a community environment. The Co-op model produces big data for AI analysis creating value for hospitals, research, drug development, and other involved in cancer care.

    Cooperatively we can all work together to improve community access to comprehensive genomic profiling and advance scientific discovery

    Genomic Testing Cooperative works with laboratories, hospitals, pathologists, oncologists, and other medical professionals to improve access to cutting edge technology in genomic testing at an affordable price by sharing resources and expertise.

    Gain access to advanced technology, molecular expertise, and a pipeline for innovation and development of new tests.

    Genomic Testing Cooperative utilizes technology innovations that integrate artificial intelligence and proprietary algorithms within our informatics tools.  These tools enable faster turnaround times of results, comprehensive reporting including targeted and immunotherapy recommendations and clinical trial options.

    What Test to Order

    State-of-the-Art Innovation

    Machine/deep Learning meets Next Generation Sequencing

    NGS

    Next generation sequencing DNA/RNA testing

    Genomic sequencing revolutionary methods never used before. Next generation sequencing has changed medicine in the past decade in ways most people couldn’t imagine. It has allowed a rapid evolution to the field of precision medicine with new drugs being approved regularly.

    Co-Op

    We work together to achieve more​

    A Cooperation Model of Bringing new solutions. Simply put a co-op means we all work together as a team to make things better. In the case of the Genomic Testing Cooperative it means that our lab works with other labs, physicians and patients to improve the communities access to cutting edge healthcare.

    AI Machine Learning

    Bringing computer science to laboratories

    Our AI helps us sort through curate large sets of data so we can quickly make sense of genomic alterations and assess their impact on a patient prognosis, diagnosis and help predict their response to therapy. We use machine learning to review these alterations and track their frequency.

    Advantages of Liquid Biopsy compared to Bone Marrow Biopsy

    Liquid Biopsy
    Bone Marrow Biopsy

    Pain free | Non-Invasive | Easily Obtained | Fast | Risk free | Accurate | Comprehensive Genomic Profile | Low Cost

    Liquid biopsy has the advantages of non-invasive, rapid, precise, and especially real-time. Liquid biopsies utilize genetic sequencing for many purposes in oncology. They can be uniquely used as a screening tool for early detection either by testing the entire sample for mutations, or looking for specific mutations in the sample.
    The emergence of non-invasive diagnostic techniques for tumors, such as liquid biopsy, marks a major step forward for humans on the road to conquering tumors. From the 2016 Food and Drug Administration (FDA) approval of the first liquid biopsy products based on EGFR gene mutations, by August 2018, tumor mutation burden in blood (bTMB) was confirmed to predict the effectiveness of immunotherapy, and liquid biopsy has already made a big splash in the field of cancer treatment.It can also overcome the heterogeneity of tumors and may replace tissue biopsy in the future. Liquid biopsy has broad application prospects in the diagnosis and treatment of cancer, including early diagnosis screening, tumor heterogeneity, drug resistance, and establishment of targets.

    Involves Pain | Invasive | Localized Sampling of  Tissue | Not Easily Obtained | Time consuming | Some Risk Involved | Expensive

    Bone marrow biopsies require solid matter from the body. This specimen is removed from bone marrow. An anesthetic may be used: local to numb area of extraction for pain, or general to make the patient unconscious. Technique involve needles and other endoscopic tools. Specimen extraction from the body require surgical methods. As a result, side effects can include risk of infection, internal bleeding, or prolonged recovery time.

    Bone marrow biopsies ant Tumor biopsies used to be irreplaceable in identifying the nature of tumors: type of cancer, gene expression of the tumor, and presence of treatment-resistant mutations. However, that is affected by several components of origin, such as tumor location, tissue amount available, and accessibility for surgical removal. The instable nature of tumors makes them heterogeneous, which means tissue from a certain area of the tumor may have radically different mutations and genetic expressions than other areas. This provides inaccurate information.

    Palmetto covers two genomic tests from GTC

    Genomic Testing Cooperative (GTC) Receives Medicare (Palmetto GBA) Coverage for two NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms.

    The Medicare Administrative Contractor Palmetto GBA (MolDx®) has finalized its review and has established coverage for two Genomic Testing Cooperative (GTC) hematology profiles:  GTC-Hematology (179 gene DNA profiling) and GTC-Hematology Plus (179 gene DNA and 1408 gene RNA profiling).

    The two Comprehensive Genomic Profile (CGP) tests are designed to help Pathologists and Hematologists/Oncologists in establishing the precise diagnosis, prognosis and determine therapy in hematologic neoplasms.

    The GTC Hematology test (179 gene DNA Profile) can be performed on cell-free DNA (cf-DNA) from peripheral blood samples representing the first Palmetto GBA covered liquid biopsy for hematology. A liquid biopsy for suspected hematologic neoplasms or monitoring patients with hematologic neoplasms can be highly useful and practical as a replacement to the painful bone marrow biopsy, which can be a deterrent for some patients.

    READ MORE

    Or Contact us today at 949-540-9421 to order and learn more about our NGS offering.

    Get Results in 7 days.

    Dr. Albitar Explains All the Competitive Advantages of GTC

    Α detailed interview

    Dr. Maher Albitar MD
    Play Video

    NGS is Enabling Medical Breakthroughs

    Next generation sequencing has changed medicine in the past decade in ways most people couldn’t imagine. It has allowed a rapid evolution to the field of precision medicine with new drugs with being approved regularly. However, it has previously been cost prohibitive with many insurance companies not covering testing. The data sets it produced were also hard to interpret and understand due to their size, complexity and lack of historical data.

    We have now reached a time where we can utilize genomic testing in a cost-effective matter. The tools are now available to make sense of the complex data. There is a large database of samples to look at and compare. In essence, we are at the tipping point of a deep understanding of cancer which we have never had before in human history and are making therapies that have the potential to cure the disease.

    Revolutionary
    Methods

    Advanced Genomic Testing

    For Patients.

    Thank you for taking the time to read this page.

    We understand right now you’re likely reading this because you have cancer
    or you know someone who does and are seeking answers.

    Cancer is a genomic disease and understanding what is happening at a genomic level helps medical professionals provide better care.

    What Cancers
    We Test for

    Don’t Miss Another Update
    Subscribe to our Newsletter

    Get all the critical news and events about genomic testing sent straight to your inbox

    Contact Us.

    Let’s talk

    Contact Info